Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19
| dc.contributor.author | Karachaliou, Marianna | |
| dc.contributor.author | Ranzani, Otavio | |
| dc.contributor.author | Espinosa, Ana | |
| dc.contributor.author | Iraola Guzmán, Susana | |
| dc.contributor.author | Castaño Vinyals, Gemma | |
| dc.contributor.author | Vidal, Marta | |
| dc.contributor.author | Jiménez, Alfons | |
| dc.contributor.author | Bañuls, Marc | |
| dc.contributor.author | Alonso Nogués, Eva | |
| dc.contributor.author | Aguilar, Ruth | |
| dc.contributor.author | García Aymerich, Judith | |
| dc.contributor.author | Cid Ibeas, Rafael de | |
| dc.contributor.author | Dobaño, Carlota | |
| dc.contributor.author | Moncunill, Gemma | |
| dc.contributor.author | Kogevinas, Manolis | |
| dc.date.accessioned | 2024-11-13T07:08:19Z | |
| dc.date.available | 2024-11-13T07:08:19Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | Limited research suggests that certain viruses reactivate in severe-acute-respiratory-syndrome-coronavirus 2 infection, contributing to the development of postacute sequelae of COVID-19 (PASC). We examined 1083 infected individuals from a population-based cohort, and assessed differences in plasma immunoglobulin (Ig)G and immunoglobulin A levels against Epstein-Barr virus (EBV), cytomegalovirus, varicella zoster virus (VZV), BK polyomavirus, KI polyomavirus, WU polyomavirus (WUPyV), respiratory syncytial virus, and Adv-36 according to the severity of previous COVID-19 and PASC history. Individuals who had experienced severe COVID-19 had higher antibody responses to latent viruses. Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher immnoglobulin G to EBV early antigen-diffuse, VZV, and WUPyV even among individuals without previous severe COVID-19. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.citation | Karachaliou M, Ranzani O, Espinosa A, Iraola-Guzmán S, Castaño-Vinyals G, Vidal M, et al. Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19. J Med Virol. 2024 Sep;96(9):e29862. DOI: 10.1002/jmv.29862 | |
| dc.identifier.doi | http://dx.doi.org/10.1002/jmv.29862 | |
| dc.identifier.issn | 0146-6615 | |
| dc.identifier.uri | http://hdl.handle.net/10230/68507 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | J Med Virol. 2024 Sep;96(9):e29862 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/HE/101046314 | |
| dc.rights | © 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.keyword | COVID‐19 | |
| dc.subject.keyword | Herpesviruses | |
| dc.subject.keyword | Long COVID | |
| dc.subject.keyword | Polyomaviruses | |
| dc.subject.keyword | Postacute sequelae of COVID‐19 | |
| dc.title | Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19 | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1
Carregant...
- Nom:
- Karachaliou_jmv_anti.pdf
- Mida:
- 634.94 KB
- Format:
- Adobe Portable Document Format

